Efficacy of Short Hydration for Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210128002

Enrollment

Registered

2021-01-28

Start date

2019-12-23

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer patients who treated with intermediate to high dose cisplatin in outpatient. Short hydration cisplatin Nephrotoxicity chemoprevention

Interventions

short hydration premedication before intermediate to high dose cisplatin with magnesium and mannitol supplement

Experimental Other

short hydration

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.cancer patients who treated with intermediate to high dose cisplatin in outpatient 2.age > 18 year 3.ECOG performance status 0-2 4. adequate renal function eGFR>60 mL/min

Exclusion criteria

Exclusion criteria: 1. underlying heart disease ,poor LV function 2.eGFR decline >20% from baseline after cisplatin administration

Design outcomes

Primary

Measure	Time frame
nephrotoxicity week 3, week6,week9,week12, week 15 after enroll eGFR	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactChaichana Chantharakhit

Division of Medical Oncology, Department of Medicine, Buddhasothorn Hospital, Chachoengsao, Thailand

chaichana.md@gmail.com0817866945

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026